SU1053750A3 - Process for preparing derivatives of isoxazole - Google Patents
Process for preparing derivatives of isoxazole Download PDFInfo
- Publication number
- SU1053750A3 SU1053750A3 SU813261940A SU3261940A SU1053750A3 SU 1053750 A3 SU1053750 A3 SU 1053750A3 SU 813261940 A SU813261940 A SU 813261940A SU 3261940 A SU3261940 A SU 3261940A SU 1053750 A3 SU1053750 A3 SU 1053750A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- group
- alkyl
- oxy
- stands
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
f, 1 Изобретение относитс к способу пол чени новых производных изоксазода, об ладающих фармакологической активность которые могут найти применение в каче ве лекарственных средств в медицине. Известен способ полу -хени изоксазол-5 илглиоксаль-2-оксимов формула N Vi . O -t H lf-Oli il . где Я водород, низший алккл или фе взаимодействием соответствующего изоксазол-З-кар льдегида с нитрнметаном -В присутствии избытка основного агента лри темпераауре от -2О до либо взаимодействием соответствующего 5-а тилизоксазола с адасилнитритом при темп ратуре от -10 до 50°С. Эти соединени обладают ripoTtrooBoc папительным и анальгетическнм действи ми Cl 3 , Цель избретени получение новых пpo iзвoдньrx изоксааола, расшир ющих арсенал средств воздействи на живой; организм. Цет-з достигаетс предлагаемым спо бом получени производных изоксазола общей формулы Ш1{о ™1 0 СН2 0-1Ш2 где f - Ц С . алкил j галоген который заключаетс : в том, что соедине ние общей формулы Iv.Е2I v-r 0- СН2-0-Ж ЖА.Х где R и . r.L R 2 имеют указан.ные значе подвергаТотвзаимодействию с гидразино Б среде хлорированного углеводорода пр комнатной температуре. Исход1йэ1е соединени путем в-закмодействи с N -оксифталимидом соединени общви, формулы W где R-т и R HMeioT указанные значени 0,2 Целевой продукт г реплочтител:ьно можно выдел ть с г омощь о сол ной кислоты в форме гицрохлорида. Получаемые согласно изобретению новые соединени формулы (1) обладают сильн1)Ш и относительно длительным понижающим кров ное давление действием, а в случае некоторых представите;1ей этой группы соедине.гп-гй набпюдаечс также прот1товоспалите. .1ъное п жаропонижающее действи , В дозе, составл ющей 1/20 от LDjQ , целевые соединени вызьвзают сильное, но кратковременное действие, В дозе составл ющей 1/10 от ., 3-метил 4г-хлор.-4-аминоьксимети т- зокса зол на 38% подавл.чет отек, вызванный локал1:, введением 0,05 млУ декCTjjaHa . на мышах. Биологически актив}1ые соединени общ.ей формулы (1) или их фармацевтически пригодные соли при прнх енетга обычньтх фармацевтичЕскизс основ и вочо- могательных веществ, vianpHMep талька, карбоната ка.псьци , стеарата магни , мела, воды, иолиалкнленг/школей, крахмалов , можно перерабатывать в готовые формы, Фармапевтическке препараты мо гут 6biTb в виде твердьсс (iianpnvjep, таб-летки , калсу Ые свечи, драже) дай жидких (например, растворы, суспензии или эмульсии) композиций. П р и м а р. а) Попуювие З-метил- гапогеи 5-броммегиг1ИчЬксазолов, Ojl модь соответствутошего 3,5.-диметил-4- галогенркзоксазод:1 раствор ю в 150 мл безводного четыреххлористого уГЛерода. После аобавкк 0,5 г перекиси бензоила раствор нагревают до кипени , К смеси в теч.енке Is54 матпькими порци ми . добав.1тают 0.12 мо гз N -бромсук- ишшмида, после чего реакнконмую смесь 4-5 ч кип т т. После охлалсдени отфильт ровь-гоают выпавший в осадок сукцкнимид. Остающийс сиропообразный 3.-ме;тил.-4- галоген™5™бромметилизоксазол без дальнейшей очистки мохаю использовгггь дл да7Ят.нейш1:к превращений. Выход 9О-1ОО%„ б) Получение 3 метил 4 -галоген-5 (4)талимидооксйметил)-изок;сазолов„ О, 1 моль 3-метил 4-галогеН 5 бром метилизоксазола раствор ют в 120 мл безводного диметилформаьнвда. После дО бавки 0,11 моль N оксифталнмида и 0,11 мохсь триэтил.амЕма смесь в течение 2 ч нагрева):эт на вод ной бане (температура 100 С). Реаккионщао смесь охлаиадают, эазбавл ют холодной водой, выпавший кристал.гпп1еский осадок отфиль ровывают, промывают холопкой водой и перекрисгаллнзуют, Перекристйллизацией из этанола полу чают 4-хлорпроизводное, выход 89%, Т.Ш1, 152-153 С. Элементный анализ дл Вычислено, % : С 53,54| ,1О; N 9.57 ; се 12,11 НайденЪ, % ,: С 53.08, Н 2,99, N 9,58 ; се 12,15 Перекристаллизацией из смеси этанол р водой получают 4-бромпроизводное, Ьыход 90%, т.пл. 154-156°С. Элементный анализ дл С.Нд BrN-O Вычислено: %: С 46,31; Н 2,59; N 8,31; В г 23,7. Найдено, % : С 47,00; Н 2,59; N 8,25; Вг 23,67. в) Получение З-метил-4-галоген-5 ами нооксимегилизоксазолов гипрохпорипЬВ., 0,14 моль 3-метил-4-галоген-5-(фта лимидоксиметил) изоксазола раствор ют в 50О мл безвошюго дихлорметана или дихлорэтана. После добавки 6О г 98%ного гидразингидрата смесь неремешиваюг при комнатной температуре в течение 16-20 ч. Вылеливигайс фталоилгидразид отфильтровывают, промывают а 1хпорэтп ном, фклтзтрат объедин ют с П{х мьгвльлпг жидкост ми и Быиаривйют дос7/-хо. Остоток раствор ют в 20О мл беаБоц.нс.го Цжра, зфир гый рост1:юр суитат п д ; ,П. с|итом магни , концентрируют примерно па треть и насьпндют cyxHi-.f газообрлзшчт. хлористым водородом, Зьг лс;к В11Гпйсм одукт оАфильтроЕываюТ; промьтппк г эфиг пм II перекристалг гзуют, 11орекркста , п:-аипе 1 из базводното этанола но;г/чг ют 4- :лорнраизводпоо, выход 87%, т.пл, 198-200 С. Элементный анализ д/ш С,., О,, « X НС :5 / Вьгхгаслено,%: С ЗОД7; Н 4,05; N 14,08; ,81; се 17,81. Найдено, % : С 30,02; Н N14,06; се 17,77; СС 17/73/ Перекристаллизацией из безвошюго этанола по.Т}ча1ат 4-б)эс }про;гзоошюе, выход 83%, т.пл. 180.. Элементньй анашш дл С Н-, х хНСе. . . J 1 22 Вычислено, % : С 24,66; П ЗД1; N11,5-, Сб14,56; Вг 32,80. Найдено, % : С 25Д1, Н 3,08, N11,37, ,50, Вг32,72.f, 1 The invention relates to a process for the preparation of new isoxazode derivatives possessing pharmacological activity that can be used as medicinal drugs in medicine. The known method of semi-hemi isoxazol-5 Ilglyoxal-2-oxime formula N Vi. O -t H lf-Oli il. where I am hydrogen, lower alkl or fe by the interaction of the corresponding isoxazole-3-car aldehyde with nitrnmethane -in the presence of an excess of the main agent at temperatures from -2o to either by the interaction of the corresponding 5-tilisoxazole with adsilonrite at a temperature of -10 to 50 ° C. These compounds have ripoTtrooBoc papillary and analgesic effects of Cl 3, the purpose of which is to obtain new proliferative isoxaol that expand the arsenal of means of influencing living matter; an organism. Zetz is achieved by the proposed method of obtaining isoxazole derivatives of the general formula Ш1 {о ™ 1 0 СН2 0-1Ш2 where f - C С. alkyl j is halogen which is: in that the compound of the general formula Iv.E2I v-r 0-CH2-0-F JAX where R and. r.L R 2 have the indicated value. Subject to the interaction with hydrazino B environment chlorinated hydrocarbon at room temperature. The outcome of the compound is by in-co-acting with N-oxyphthalimide of the compound of the formula W, where R is r and R HMeioT, the indicated values are 0.2. Target product of the reporter: but it can be separated with hydrochloric acid in the form of hydrochloride. The new compounds of the formula (1) obtained according to the invention have a strong1) III and relatively long-term blood pressure lowering action, and in the case of some, present the first group of this compound, which also combines inflammation. .1 Antipyretic effect, At a dose of 1/20 of LDjQ, the target compounds have a strong but short-term effect. At a dose of 1/10 of. 3-methyl 4g-chloro. 4-amino-himetyxone angry at 38% suppressed swelling caused by locale1 :, administering 0.05 ml of decCTjjaHa. in mice. Biologically active} 1st compounds of general formula (1) or their pharmaceutically acceptable salts for the sale of conventional pharmaceutical bases and secondary substances, vianpHMep talc, carbonate ca. pcci, magnesium stearate, chalk, water, and alkaline / school, starch, can be processed into ready-made forms; Pharmaceutical preparations can be 6biTb in the form of hardness (iianpnvjep, tablets, kalsa) Candidates, pills, give liquid (for example, solutions, suspensions or emulsions) compositions. PRI m and p. a) Pulling out 3-methyl-gapogey 5-brommegig1Hyxazoles, Ojl mode corresponding to 3,5.-dimethyl-4-halogenoxide: 1 solution s in 150 ml of anhydrous uLLerod tetrachloride. After addition of 0.5 g of benzoyl peroxide, the solution is heated to boiling. To the mixture in Is54, the mixture is processed in small portions. The addition of 1 .0.0 MO of N-bromosuk-Shshmid is added, after which the reaction mixture is boiled for 4-5 hours. After cooling the filter, the precipitated succnimide precipitates. The remaining syrupy 3.-me; thi.-4-halogen ™ 5 ™ bromomethylisoxazole without further purification is mossing the use of it to give 7% gum1: to transformations. Yield of 9O-1OO% b) Preparation of 3 methyl 4 -halogen-5 (4) thalimidooxyl) isle; sazolus O, 1 mol of 3-methyl 4-haloH 5 bromo methylisoxazole is dissolved in 120 ml of anhydrous dimethylformacene. After addition, 0.11 mol N oxyphthalmide and 0.11 moss / triethyl / AMA mixture for 2 h of heating): in a water bath (temperature 100 ° C). The reaction mixture is cooled, ejected with cold water, the precipitated crystalline precipitate is filtered off, washed with boiling water and recrystallized, 4-chloro-derivative is obtained by recrystallization from ethanol, 89% yield, T.Sh1, 152-153 C. The elemental analysis is calculated. %: C 53.54 | , 1O; N 9.57; ce 12.11; Naiden,%; C 53.08; H 2.99; N 9.58; ce 12,15 By recrystallization from ethanol with water, 4-bromo-derivative is obtained, yield 90%, m.p. 154-156 ° C. Elemental analysis for C. Nd BrN-O Calculated:%: C, 46.31; H 2.59; N 8.31; In g 23.7. Found,%: C 47.00; H 2.59; N 8.25; Br 23.67. c) Preparation of 3-methyl-4-halogen-5 amioxymegylisoxazoles of hyprochoryp B, 0.14 mol of 3-methyl-4-halogen-5- (ft-limidoxymethyl) isoxazole is dissolved in 50 O ml of anhydrous dichloromethane or dichloroethane. After the addition of 6O g of 98% hydrazine hydrazine, the mixture is not stirred at room temperature for 16–20 h. The leaching of phthaloyl hydrazide is filtered off, washed with 1 x naphthite, fluorohydrate is combined with Pf xyllfluid fluids and Bioriwot dos7 / -ho. The effluent is dissolved in 20 ml of beaBoc. Nsgo zhra, zfirgy growth1: yur suiteat n d; ,P. with magnesium, it is concentrated by about a third and cyxHi-.f gas-purgate. hydrogen chloride, hpl; to V11Gpysm product OAfiltroEvayuT; Industrial grade g of ester PM II recrystalline, 11 electrons, n: -aipe 1 from basalter ethanol but; g / 4g: lorra production, 87% yield, mp, 198-200 C. Elemental analysis of d / w C ,. O, “X NA: 5 / Vgghasleno,%: S ZOD7; H 4.05; N 14.08; , 81; All 17.81. Found,%: C 30.02; H N14.06; All 17.77; CC 17/73 / Recrystallization from non-ethanol according to T. Ch1at 4-b) es} pro; gosoohe, yield 83%, m.p. 180 .. Element anashish for C HH, x hNSE. . . J 1 22 Calculated,%: C 24.66; P ZD1; N11.5-, Sat14.56; Br 32.80. Found,%: C 25D1, H 3.08, N11.37,, 50, Br32.72.
Claims (1)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU8080637A HU180567B (en) | 1980-03-19 | 1980-03-19 | Method for producing derivatives of isooxazole |
Publications (1)
Publication Number | Publication Date |
---|---|
SU1053750A3 true SU1053750A3 (en) | 1983-11-07 |
Family
ID=10950573
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU813261940A SU1053750A3 (en) | 1980-03-19 | 1981-03-19 | Process for preparing derivatives of isoxazole |
SU823414099A SU1152518A3 (en) | 1980-03-19 | 1982-04-01 | Method of obtaining isoxazole derivatives |
SU823416146A SU1158044A3 (en) | 1980-03-19 | 1982-04-01 | Method of obtaining 3-methyl-4-chlorine-5-bromethylaminomethylisoxazole or hydrochloride thereof |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU823414099A SU1152518A3 (en) | 1980-03-19 | 1982-04-01 | Method of obtaining isoxazole derivatives |
SU823416146A SU1158044A3 (en) | 1980-03-19 | 1982-04-01 | Method of obtaining 3-methyl-4-chlorine-5-bromethylaminomethylisoxazole or hydrochloride thereof |
Country Status (15)
Country | Link |
---|---|
JP (1) | JPS56158774A (en) |
BE (1) | BE887954A (en) |
CA (1) | CA1163631A (en) |
CH (1) | CH646157A5 (en) |
DE (1) | DE3110817A1 (en) |
DK (3) | DK151012C (en) |
ES (3) | ES501095A0 (en) |
FI (1) | FI70011C (en) |
FR (1) | FR2478634A1 (en) |
GB (1) | GB2075009B (en) |
HU (1) | HU180567B (en) |
IT (1) | IT1211010B (en) |
SE (1) | SE454695B (en) |
SU (3) | SU1053750A3 (en) |
YU (1) | YU42560B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6100260A (en) * | 1997-04-21 | 2000-08-08 | Sumitomo Pharmaceutical Company, Limited | Isoxazole derivatives |
DE69832270T2 (en) * | 1997-04-21 | 2006-07-13 | Dainippon Sumitomo Pharma Co., Ltd. | isoxazole |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL302496A (en) * | 1962-12-22 | |||
US3808221A (en) * | 1971-04-14 | 1974-04-30 | Hoffmann La Roche | Antiandrogenic n-(3,5-dilower alkyl-4-heterocyclic)methyl)phthalimides |
-
1980
- 1980-03-19 HU HU8080637A patent/HU180567B/en not_active IP Right Cessation
-
1981
- 1981-03-16 BE BE1/10179A patent/BE887954A/en not_active IP Right Cessation
- 1981-03-17 SE SE8101703A patent/SE454695B/en not_active IP Right Cessation
- 1981-03-17 YU YU689/81A patent/YU42560B/en unknown
- 1981-03-18 DK DK122581A patent/DK151012C/en not_active IP Right Cessation
- 1981-03-18 FR FR8105378A patent/FR2478634A1/en active Granted
- 1981-03-18 CH CH182981A patent/CH646157A5/en not_active IP Right Cessation
- 1981-03-18 FI FI810838A patent/FI70011C/en not_active IP Right Cessation
- 1981-03-18 IT IT8120395A patent/IT1211010B/en active
- 1981-03-18 GB GB8108545A patent/GB2075009B/en not_active Expired
- 1981-03-18 ES ES501095A patent/ES501095A0/en active Granted
- 1981-03-19 CA CA000373380A patent/CA1163631A/en not_active Expired
- 1981-03-19 SU SU813261940A patent/SU1053750A3/en active
- 1981-03-19 JP JP4023281A patent/JPS56158774A/en active Pending
- 1981-03-19 DE DE19813110817 patent/DE3110817A1/en not_active Withdrawn
-
1982
- 1982-04-01 SU SU823414099A patent/SU1152518A3/en active
- 1982-04-01 SU SU823416146A patent/SU1158044A3/en active
- 1982-04-16 ES ES511895A patent/ES511895A0/en active Granted
- 1982-04-16 ES ES511894A patent/ES8401758A1/en not_active Expired
-
1987
- 1987-01-16 DK DK023187A patent/DK153549C/en not_active IP Right Cessation
- 1987-01-16 DK DK023087A patent/DK151959C/en not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
1. За вка FR № 2419289, кп. С O7l.261/O8, опубл. 1979. * |
Also Published As
Publication number | Publication date |
---|---|
ES511894A0 (en) | 1984-01-01 |
ES8305340A1 (en) | 1983-05-01 |
DE3110817A1 (en) | 1982-03-04 |
SU1152518A3 (en) | 1985-04-23 |
DK23187A (en) | 1987-01-16 |
FI70011B (en) | 1986-01-31 |
ES8302674A1 (en) | 1983-02-16 |
IT1211010B (en) | 1989-09-29 |
DK151959B (en) | 1988-01-18 |
CA1163631A (en) | 1984-03-13 |
ES511895A0 (en) | 1983-05-01 |
JPS56158774A (en) | 1981-12-07 |
CH646157A5 (en) | 1984-11-15 |
FI70011C (en) | 1986-09-12 |
DK122581A (en) | 1981-09-20 |
YU42560B (en) | 1988-10-31 |
FR2478634B1 (en) | 1983-11-10 |
SE8101703L (en) | 1981-09-20 |
GB2075009A (en) | 1981-11-11 |
FR2478634A1 (en) | 1981-09-25 |
FI810838L (en) | 1981-09-20 |
ES8401758A1 (en) | 1984-01-01 |
IT8120395A0 (en) | 1981-03-18 |
DK23087A (en) | 1987-01-16 |
DK151012C (en) | 1988-07-04 |
DK151959C (en) | 1988-07-11 |
SE454695B (en) | 1988-05-24 |
ES501095A0 (en) | 1983-02-16 |
GB2075009B (en) | 1983-11-30 |
DK151012B (en) | 1987-10-12 |
SU1158044A3 (en) | 1985-05-23 |
BE887954A (en) | 1981-09-16 |
DK153549B (en) | 1988-07-25 |
YU68981A (en) | 1983-10-31 |
HU180567B (en) | 1983-03-28 |
DK153549C (en) | 1988-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU820659A3 (en) | Method of preparing 4-amino-5-alkylsulfonyl-o-anisamide derivatives,their salts,oxides,left-and right-rotational isomers (their variations) | |
KR100371297B1 (en) | Substituted Thiazolidinedione Derivatives | |
SU1436872A3 (en) | Method of producing derivatives of pyrimidine | |
JPH01246265A (en) | 4-pyrridone-3-carboxylic acid derivative | |
US4067982A (en) | Aryl-substituted piperazinyl-alkylamino-uracils, -uracil ethers and -uracil thioethers as therapeutics | |
DK162638B (en) | METHOD OF ANALOGY FOR THE PREPARATION OF 6-FLUORO-1,4-DIHYDRO-4-OXO-3-QUINOLINCARBOXYLIC ACID DERIVATIVES AND PROCEDURES FOR USING THE PROCEDURE | |
AU574129B2 (en) | Arylacetic acid derivatives | |
US5258397A (en) | 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions | |
IL23338A (en) | N-phenylpiperazine compounds | |
IE49541B1 (en) | 4,5-dihydro-1-(3-mercapto-1-oxopropyl)-3-phenyl-1h-pyrazole-5-carboxylic acid and derivatives thereof | |
SU1053750A3 (en) | Process for preparing derivatives of isoxazole | |
SU1635899A3 (en) | Process for preparing 3-[(1h-imidazol-4-yl)methyl]-2- oxybenzene methanols | |
ES2519441T3 (en) | Compounds to treat impotence | |
JPH033669B2 (en) | ||
JPH0699307B2 (en) | Anti-dementia agent | |
KR920005827B1 (en) | Benzothiadiazepine derivatives | |
SU784763A3 (en) | Method of preparing 6-methoxy-2-acetylnaphthyloxime derivatives of their hydrochlorides | |
US3833594A (en) | Amino derivatives of pyrazolopyridine carboxylic acids and esters | |
US4421754A (en) | Syndonimine derivatives, process for production thereof, and use thereof | |
US3862947A (en) | Intermediate for production of alkoxy derivatives of pyrazolopyridine carboxylic acids and esters | |
FR2465733A1 (en) | NOVEL IMIDAZOLYLETHOXYMETHYLIC DERIVATIVES OF 1,3-DIOXOLOQUINOLINES USEFUL AS ANTIBACTERIAL AND ANTIFUNGAL DRUGS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITIONS AND PHARMACEUTICAL FORMS CONTAINING THEM | |
US3133933A (en) | Certain | |
US4269848A (en) | 5-Substituted indan-2-carboxylic acid and functional derivatives | |
JP3553158B2 (en) | Pyridazinoindole derivatives | |
US3697527A (en) | Doethyl phenyl sulfonylureas |